Empowering living medicines.
Encellin is focused on advancing next generation therapies, starting with endocrine disorders.
The cell is the original smart machine. All drugs, devices, digital health, and even AI approaches are trying to mirror cellular functions.
OUR SOLUTION
A new category of medicine, with early clinical data.
Living medicine, infinitly programmable. Cells play complex roles to ensure our health and safety. When cells are missing, damaged or diseased the body cannot function correctly.
ENCRT (Encapsulated Cell Replacement Therapy) is a modular system: any therapeutic cell type can be loaded into it, protected, and enabled to function as a living drug factory inside the body.
Starting with: Endocrine Disorders
On January 6th, 2026, Encellin reported positive interim results of its Phase 1 clinical trial of encapsulated islets in people with type 1 diabetes (T1D).
